Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19–Associated Hospitalization Among Adults with Previous SARS-CoV-2 Infection — U.S. June 2021–February 2022

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Personal Author:
  Plumb, Ian D. ; Feldstein, Leora R. ; Barkley, Eric ; Posner, Alexander B. ; Bregman, Howard S. ; Hagen, Melissa Briggs ; Gerhart, Jacqueline L.
• Description:
  Previous infection with SARS-CoV-2, the Virus that causes COVID-19, has been estimated to confer up to 90% protection against reinfection, although this protection was lower against the Omicron Variants compared with that against other SARS-CoV-2 Variantss (1-3). A test-negative design was used to estimate effectiveness of COVID-19 mRNA vaccines in preventing subsequent COVID-19-associated hospitalization among adults aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or Diagnosis of COVID-19.| The Analysis used data from Cosmos, an electronic health record (EHR)-aggregated data set (4), and compared vaccination status of 3,761 case-patients (positive NAAT result associated with hospitalization) with 7,522 matched control-patients (negative NAAT result). After previous SARS-CoV-2 infection, estimated vaccine effectiveness (VE) against COVID-19-associated hospitalization was 47.5% (95% CI = 38.8%-54.9%) after 2 vaccine doses and 57.8% (95% CI = 32.1%-73.8%) after a booster dose during the Delta-predominant period (June 20-December 18, 2021), and 34.6% (95% CI = 25.5%-42.5%) after 2 doses and 67.6% (95% CI = 61.4%-72.8%) after a booster dose during the Omicron-predominant period (December 19, 2021-February 24, 2022). Vaccination provides protection against COVID-19-associated hospitalization among adults with previous SARS-CoV-2 infection, with the highest level of protection conferred by a booster dose. All eligible persons, including those with previous SARS-CoV-2 infection, should stay up to date with vaccination to prevent COVID-19-associated hospitalization.
• Subjects:
  Adolescent Adult COVID-19 Hospitalization Humans RNA, Messenger SARS-CoV-2 Vaccination
• Source:
  MMWR Morbidity Mortal Weekly Rep. 71(15):549-555
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/MMWRmm7115e2
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  35421077
• Pubmed Central ID:
  PMC9020856
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  71
• Issue:
  15
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:015eec00699e0a6f2d5a0e455bb2ee6cdc164275559d22b5a160995a7bb84413884e366c1a0244375d0fe1a7b7c9228f953fd82975975a78d724c74dc2a5f797
• Download URL:
  https://stacks.cdc.gov/view/cdc/117047/cdc_117047_DS1.pdf
• File Type:
  [PDF - 145.02 KB ]